1227862-29-4Relevant academic research and scientific papers
Discovery of highly potent, selective, covalent inhibitors of JAK3
Kempson, James,Ovalle, Damaso,Guo, Junqing,Wrobleski, Stephen T.,Lin, Shuqun,Spergel, Steven H.,Duan, James J.-W.,Jiang, Bin,Lu, Zhonghui,Das, Jagabandhu,Yang, Bingwei V.,Hynes, John,Wu, Hong,Tokarski, John,Sack, John S.,Khan, Javed,Schieven, Gary,Blatt, Yuval,Chaudhry, Charu,Salter-Cid, Luisa M.,Fura, Aberra,Barrish, Joel C.,Carter, Percy H.,Pitts, William J.
, p. 4622 - 4625 (2017)
A useful and novel set of tool molecules have been identified which bind irreversibly to the JAK3 active site cysteine residue. The design was based on crystal structure information and a comparative study of several electrophilic warheads.
PYRIDINE-3-CARBOXYAMIDE DERIVATIVE
-
Page/Page column 29, (2011/10/12)
To provide a novel JAK3 inhibitor that is useful as a preventive and/or therapeutic agent for rejection and graft versus host disease (GvHD) in organ transplantation, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, Sj?gren syndrome, Behcet's disease, type I diabetes mellitus, autoimmune thyroiditis, idiopathic thrombocytopenic purpura, ulcerative colitis, Crohn's disease, asthma, allergic rhinitis, atopic dermatitis, contact dermatitis, urticaria, eczema, psoriasis, allergic conjunctivitis, uveitis, cancer, leukemia and the like. The pyridine-3-carboxyamide derivative represented by the general formula (1): or its salt or a solvate thereof.
